


What is your usual neoadjuvant systemic therapy recommendation for a 70-year-old patient with borderline resectable pancreatic cancer?



Would you generally administer neoadjuvant therapy to a 70-year-old patient with pancreatic adenocarcinoma that appears to be resectable?

Yes

64%




No


36%




What is your likely adjuvant systemic therapy recommendation for an otherwise healthy 75-year-old patient who is s/p surgical resection of pancreatic adenocarcinoma?




Have you administered adjuvant gemcitabine/*nab* paclitaxel to a patient with pancreatic cancer outside of a clinical trial setting?




In general, what would you recommend for an otherwise healthy patient with localized pancreatic cancer that is not surgically resectable?




In general, what treatment would you recommend for a patient with pancreatic cancer who develops metastatic disease 5 months after neoadjuvant FOLFIRINOX followed by surgical resection?




In general, what treatment would you recommend for a patient with pancreatic cancer who develops metastatic disease 5 months after surgical resection followed by adjuvant gemcitabine/capecitabine?




In general, what treatment would you recommend for an 75-year-old patient with de novo metastatic pancreatic cancer and a performance status of 0?




What is the age of the oldest patient to whom you've administered FOLFIRINOX or modified FOLFIRINOX as first-line therapy for metastatic pancreatic cancer?




In general, what treatment would you recommend for a 65-year-old patient with de novo metastatic pancreatic cancer who is ambulatory but unable to work?




A 72-year-old patient who is not a candidate for FOLFIRINOX receives gemcitabine/*nab* paclitaxel for metastatic pancreatic cancer and experiences disease progression after 6 cycles. What second-line therapy would you recommend?




What is your usual second-line therapy for a patient who receives first-line FOLFIRINOX for metastatic pancreatic cancer and experiences disease progression?



In general, what treatment would you recommend for a patient who receives first-line modified FOLFIRINOX followed by second-line gemcitabine/*nab* paclitaxel for metastatic pancreatic cancer and experiences disease progression?



Which of the following do you routinely assess for your patients with metastatic pancreatic cancer and no significant family history of cancer?



Have you or would you administer a PARP inhibitor to a patient with metastatic pancreatic cancer and a BRCA germline mutation?



Have you observed an objective response to an anti-PD-1/PD-L1 antibody in a patient with metastatic pancreatic cancer?

